Cambridge Healthtech Institute’s Inaugural

Modality Selection for Next-Gen Biotherapeutics

Exploring the State of the Science, Clinical Considerations, and Challenges in Biotherapeutic Drug Products

September 17-18, 2020

 

As the industry gains more experiences with biotherapeutics, the concept of an agnostic approach to modality selection is becoming more common in early discovery, with the premise of automatically moving a target into a given product format and giving way to a comprehensive examination of alternatives. New screening assays and technologies and a trend toward pushing functional studies earlier in the process are blending with an increasing range of options for achieving desired specificity, MOA and safety. DOT's Modality Selection for Next-Gen Biotherapeutics conference considers the state of the science for complex antibody formats, expanding applications of cell and gene therapies, and clinical perspectives on the use of biotherapeutics in patients. The program also examines options for unique circumstances including receptor agonism, alternate routes of administration, and delivery to the brain and CNS.

Preliminary Agenda

KEYNOTE PRESENTATION: Multifunctional Antibody and Cell-Based Therapeutics: The Last Frontier

Lakshmi Krishnan, PhD, Director General, Human Health Therapeutics Research Center, National Research Council, Canada

STATE OF THE SCIENCE FOR BIOTHERAPEUTIC MODALITIES

Advances and Future Directions for Bispecific Antibodies

Eugene Zhukovsky, CSO, Biomunex Pharmaceuticals; Manager and Partner at ZM Scientific LLC

AAV Capsid Evolution: Applications for Targeted Delivery

Ben Deverman, PhD, Director, Vector Engineering Research, Broad Institute of MIT and Harvard

Challenges and Opportunities in CAR-T Cell Treatment of Hematological Malignancies

Challice Bonifant, MD, PhD, Assistant Professor, Oncology, Johns Hopkins University

CAR-Ts and NKs

Dimiter Dimitrov, PhD, Professor and Director, Center for Antibody Therapeutics, University of Pittsburgh

SPECIAL PRESENTATION

How Uncertainty in Patentability Will Impact Modality Selection for Biotherapeutics

John Conley, PhD, JD, Professor, University of North Carolina School of Law

CLINICAL PERSPECTIVES ON BIOTHERAPEUTIC MODALITIES

Integration of Discovery with Clinical Translation in Biologics and Cell Therapy

Dongxing Zha, PhD, Head, Oncology Research for Biologics and Immunotherapy Translation (ORBIT) Platform, MD Anderson Cancer Center

New Biotherapeutic Approaches for Targeting PCSK9

Robert Giugliano, MD, MSc, Professor, Medicine, Harvard Medical School

SPECIAL PRESENTATION

Monoclonal Antibodies 45 Years Later: Current Landscape of Antibodies and Antibody-Related Molecules

William Strohl, PhD, Owner and President, BiStro Biotech Consulting LLC; former Vice President, Janssen Biotherapeutics

R&D TOOLS AND WORKFLOWS

Structure of CD20 in Complex with the Therapeutic Monoclonal Antibody Rituximab

Lionel Rougé, PhD, Principal Scientific Researcher, Genentech

High-Throughput Discovery of Antibodies to Multi-Spanning Membrane Proteins

Noel Pauli, PhD, Senior Scientist, Adimab LLC

Next Generation Strategies for Antibody Discovery to Membrane Proteins

Brian Booth, PhD, Senior Scientist, Drug Discovery, Visterra

Talk Title to be Announced

Anna Yarilina, PhD, Senior Scientist, AbbVie Bioresearch Center




For more details on the conference, please contact:
Kent Simmons

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+1) 207-869-9199
Email: ksimmons@healthtech.com

 

For partnering and sponsorship information, please contact:
Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286
Email: reymael@healthtech.com